(RS)-hydroxyzine (Q421937)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

group of stereoisomers

Language	Label	Description	Also known as
English	(RS)-hydroxyzine	group of stereoisomers

Statements

group of stereoisomers

0 references

monochlorobenzene

0 references

0 references

0 references

primary alcohol

0 references

0 references

chemical structure

Hydroxyzine.svg
512 × 300; 12 KB

0 references

374.176106 dalton

1 reference

language of work or name

hydroxyzine (English)

3 October 2016

chemical formula

C₂₁H₂₇ClN₂O₂

1 reference

language of work or name

hydroxyzine (English)

19 November 2016

canonical SMILES

C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl

1 reference

language of work or name

hydroxyzine (English)

19 November 2016

defined daily dose

75 milligram

route of administration

oral administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=N05BB01

75 milligram

route of administration

parenteral route of administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=N05BB01

active ingredient in

1 reference

14 February 2018

1 reference

14 February 2018

World Health Organisation international non-proprietary name

hydroxyzine (English)

1 reference

language of work or name

hydroxyzine (English)

3 October 2016

medical condition treated

anxiety disorder

1 reference

language of work or name

13 December 2016

1 reference

language of work or name

13 December 2016

1 reference

Drug Indications Extracted from FAERS

2 October 2018

significant drug interaction

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

arsenic trioxide

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(±)-promethazine

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

cognitive disorder

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

central respiratory depression

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

depressed level of consciousness

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

Histamine receptor H1

subject has role

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

pregnancy category

Australian pregnancy category A

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category E

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Hydroxyzine

16 January 2017

subject has role

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

histamine antagonist

1 reference

5 March 2018

2 references

5 March 2018

Medical Subject Headings

MeSH descriptor ID

15 March 2018

hydrOXYzine

has characteristic

Tall Man lettering

Food and Drug Administration

subject named as

Hydroxyzine

1 reference

https://www.fda.gov/drugs/medication-errors-related-cder-regulated-drug-products/fda-name-differentiation-project

2 September 2022

Commons category

Hydroxyzine

0 references

Identifiers

InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2

1 reference

language of work or name

hydroxyzine (English)

19 November 2016

ZQDWXGKKHFNSQK-UHFFFAOYSA-N

2 references

language of work or name

hydroxyzine (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

2 references

Global Substance Registration System

language of work or name

hydroxyzine (English)

19 November 2016

ZQDWXGKKHFNSQK-UHFFFAOYSA-N

CAS Common Chemistry

10 April 2021

https://commonchemistry.cas.org/detail?cas_rn=68-88-2

1 reference

language of work or name

Hydroxyzine (English)

19 November 2016

2 references

language of work or name

hydroxyzine (English)

19 November 2016

matched by identifier from

ZQDWXGKKHFNSQK-UHFFFAOYSA-N

Reaxys registry number

321392

1 reference

language of work or name

hydroxyzine (English)

3 October 2016

mapping relation type

2 references

language of work or name

HYDROXYZINE (English)

19 November 2016

matched by identifier from

International Chemical Identifier

InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2

1 reference

language of work or name

HYDROXYZINE (English)

19 November 2016

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

ZQDWXGKKHFNSQK-UHFFFAOYSA-N

UniChem compound ID

1 reference

MassBank accession ID

MSBNK-Fac_Eng_Univ_Tokyo-JP003071

0 references

MSBNK-Waters-WA002927

0 references

MSBNK-Waters-WA002928

0 references

MSBNK-Waters-WA002929

0 references

MSBNK-Waters-WA002930

0 references

MSBNK-Waters-WA002931

0 references

MSBNK-Waters-WA002932

0 references

splash10-0uxr-4591000000-d2e3424c44feae8a5d9c

0 references

1 reference

Hazardous Substances Data Bank

publication date

28 October 2019

HYDROXYZINE (English)

10 May 2021

DSSTox substance ID

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

matched by identifier from

ZQDWXGKKHFNSQK-UHFFFAOYSA-N

DSSTOX compound identifier

0 references

0 references

0 references

1 reference

Global Substance Registration System

language of work or name

hydroxyzine (English)

19 November 2016

ECHA Substance Infocard ID

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

Hydroxyzine (English)

CAS no.: 68-88-2 (English)

0 references

1 reference

language of work or name

Hydroxyzine (English)

publication date

17 November 2015

World Health Organisation international non-proprietary name numeric ID

0 references

Guide to Pharmacology Ligand ID

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

hydroxyzine (English)

19 November 2016

MeSH descriptor ID

subject named as

Hydroxyzine

0 references

D03.383.606.515

0 references

1 reference

Global Substance Registration System

language of work or name

hydroxyzine (English)

19 November 2016

1 reference

matched by identifier from

ZQDWXGKKHFNSQK-UHFFFAOYSA-N

Human Metabolome Database ID

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

ZQDWXGKKHFNSQK-UHFFFAOYSA-N

2 references

Global Substance Registration System

language of work or name

hydroxyzine (English)

19 November 2016

matched by identifier from

ZQDWXGKKHFNSQK-UHFFFAOYSA-N

MedlinePlus drug identifier

0 references

PatientsLikeMe treatment ID

0 references

1 reference

Global Substance Registration System

language of work or name

hydroxyzine (English)

19 November 2016

Probes And Drugs ID

0 references

1 reference

1 reference

language of work or name

hydroxyzine (English)

3 October 2016

1 reference

language of work or name

hydroxyzine (English)

3 October 2016

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

200907035832319226

0 references

Microsoft Academic ID

0 references

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

1 reference

1 reference

Global Substance Registration System

language of work or name

hydroxyzine (English)

19 November 2016

WikiProjectMed ID

0 references

Sitelinks

Wikipedia(33 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswiki Category:Hydroxyzine

Retrieved from "https://www.wikidata.org/w/index.php?title=Q421937&oldid=2264884371"